Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
AshvsEvilDead
AshvsEvilDead Jan. 12 at 4:58 AM
$BCLI My thoughts: One of the biggest hurdles in CMC a non issue now. It mitigates any last technical excuse on CMC and removes FDA cover for non approval. Today with some extraordinarily good news for Brainstorm and ALS patients. Focus shifts now to approval. https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation
0 · Reply
DoctorJT
DoctorJT Jan. 12 at 1:40 AM
$BCLI https://x.com/andrewcaravello/status/2010511035501838342?s=46 From the head of the FDAs mouth RE: cell and gene therapies.
0 · Reply
Condo3e
Condo3e Jan. 11 at 5:23 PM
$BCLI It's important to note, quantum computing, NurOwn, and Brainstorms Exosome program are all linked together.
0 · Reply
afc2881
afc2881 Jan. 11 at 12:03 AM
$BCLI Looks like Chaim got some expensive financing. I hope he has a plan for repayment!
3 · Reply
afc2881
afc2881 Jan. 11 at 12:01 AM
$BCLI New 8-K filed 1-9. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319696230&type=PDF&symbol=BCLI&cdn=b5cf227ab280bc28ffa7a82b6e420019&companyName=Brainstorm+Cell+Therapeutics+Inc.&formType=8-K&dateFiled=2026-01-09
1 · Reply
Condo3e
Condo3e Jan. 10 at 9:15 PM
$BCLI As quantum computing advances, it could be possible to find places where NurOwn could help people with developmental issues in conjunction with other therapies.
0 · Reply
Mobagri
Mobagri Jan. 10 at 4:38 PM
$BCLI When is the next investor conference call??
2 · Reply
Condo3e
Condo3e Jan. 9 at 12:38 PM
$BCLI Becky Quick and Need for New Therapies Becky Quick's initiative, CNBC Cures, aims to raise awareness and improve patient outcomes for rare diseases. The initiative is led by Becky Quick, who is inspired by her family's journey with Kaylie's SYNGAP1 disorder. The initiative focuses on identifying barriers that slow advancements in rare disease treatments and aims to bring attention to the need for new therapies. Becky Quick's story and the challenges faced by families with rare diseases highlight the urgent need for research and development of new treatments to improve the lives of those affected by these conditions.
0 · Reply
Pipemajors82
Pipemajors82 Jan. 8 at 2:57 PM
$BCLI https://www.facebook.com/share/1D12uVxTV7/
0 · Reply
Condo3e
Condo3e Jan. 7 at 11:43 AM
$BCLI I would not expect Brainstorm to release any news until after the 2026 stock grants are issued
1 · Reply
Latest News on BCLI
No data available.
AshvsEvilDead
AshvsEvilDead Jan. 12 at 4:58 AM
$BCLI My thoughts: One of the biggest hurdles in CMC a non issue now. It mitigates any last technical excuse on CMC and removes FDA cover for non approval. Today with some extraordinarily good news for Brainstorm and ALS patients. Focus shifts now to approval. https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation
0 · Reply
DoctorJT
DoctorJT Jan. 12 at 1:40 AM
$BCLI https://x.com/andrewcaravello/status/2010511035501838342?s=46 From the head of the FDAs mouth RE: cell and gene therapies.
0 · Reply
Condo3e
Condo3e Jan. 11 at 5:23 PM
$BCLI It's important to note, quantum computing, NurOwn, and Brainstorms Exosome program are all linked together.
0 · Reply
afc2881
afc2881 Jan. 11 at 12:03 AM
$BCLI Looks like Chaim got some expensive financing. I hope he has a plan for repayment!
3 · Reply
afc2881
afc2881 Jan. 11 at 12:01 AM
$BCLI New 8-K filed 1-9. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319696230&type=PDF&symbol=BCLI&cdn=b5cf227ab280bc28ffa7a82b6e420019&companyName=Brainstorm+Cell+Therapeutics+Inc.&formType=8-K&dateFiled=2026-01-09
1 · Reply
Condo3e
Condo3e Jan. 10 at 9:15 PM
$BCLI As quantum computing advances, it could be possible to find places where NurOwn could help people with developmental issues in conjunction with other therapies.
0 · Reply
Mobagri
Mobagri Jan. 10 at 4:38 PM
$BCLI When is the next investor conference call??
2 · Reply
Condo3e
Condo3e Jan. 9 at 12:38 PM
$BCLI Becky Quick and Need for New Therapies Becky Quick's initiative, CNBC Cures, aims to raise awareness and improve patient outcomes for rare diseases. The initiative is led by Becky Quick, who is inspired by her family's journey with Kaylie's SYNGAP1 disorder. The initiative focuses on identifying barriers that slow advancements in rare disease treatments and aims to bring attention to the need for new therapies. Becky Quick's story and the challenges faced by families with rare diseases highlight the urgent need for research and development of new treatments to improve the lives of those affected by these conditions.
0 · Reply
Pipemajors82
Pipemajors82 Jan. 8 at 2:57 PM
$BCLI https://www.facebook.com/share/1D12uVxTV7/
0 · Reply
Condo3e
Condo3e Jan. 7 at 11:43 AM
$BCLI I would not expect Brainstorm to release any news until after the 2026 stock grants are issued
1 · Reply
Condo3e
Condo3e Jan. 7 at 1:49 AM
$BCLI Using Microsoft Co Pilot, research NurOwn and Quantum Computing
0 · Reply
Condo3e
Condo3e Jan. 7 at 1:30 AM
$BCLI The effort to help those sadly diagnosed with ALS has been a noble effort, and yes, NurOwn should have been approved in 2023. The issue today is simple, what is their data worth, what is reason for the company going underground, and since lawyers like to get paid, who is paying for the great work behind the citizen's petition, let's face it, these are certainly interesting times following the Days of Brainstorm.
1 · Reply
Condo3e
Condo3e Jan. 6 at 7:26 PM
$BCLI Quantum Computing will validate what people believe, NurOwn is worth billions.
1 · Reply
Knuckles30
Knuckles30 Jan. 6 at 4:36 PM
$BCLI Great job by our military!!! if we can get Maduro that quick what the hell is the FDA doing. Our people are dying while the FDA is pushing back answers on a chance to save the lives of these patients!!!
2 · Reply
Kgra
Kgra Jan. 6 at 1:11 AM
$BCLI https://alsnewstoday.com/news/coya-302-alstars-trial-us-expands-canada-following-regulatory-okay/
0 · Reply
Pipemajors82
Pipemajors82 Jan. 2 at 2:56 PM
$BCLI im thinkkng probably no news for 60-90 days. Am i being optimistic?
1 · Reply
moneymike89
moneymike89 Jan. 2 at 4:47 AM
$BCLI They didn't even run the trial yet right?
1 · Reply
ALSCellTherapy
ALSCellTherapy Jan. 1 at 7:16 AM
$BCLI Paragraph 4 Finally, while the law speaks in terms of “unreasonable” delay, in a case like this there is no delay that is reasonable. Any delay here equates to irreversible loss, and our harm is literal death. I feel that reality every day in my own body, and every time we lose someone while waiting. I will not sit idly by while another brother, sister, spouse, parent, or child is lost to this disease. That reality is unacceptable to me, and it fuels my determination to fight for meaningful progress.
1 · Reply
ALSCellTherapy
ALSCellTherapy Jan. 1 at 7:15 AM
$BCLI Paragraph 3 Courts routinely step in when delays become unreasonable, weighing factors such as agency priorities, complexity, and critically, the harm to petitioners. Most citizen petitions do not carry the same profound urgency as ours. Few involve therapies as critical as Nurown. Moreover, we are not the average petitioners. We have approached this process from a data-driven and legally grounded perspective.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jan. 1 at 7:13 AM
$BCLI Paragraph 2 Long answer and, more fundamentally, the Administrative Procedure Act imposes a binding duty. Under 5 U.S.C. § 555(b), “With due regard for the…necessity of the parties…and within a reasonable time, each agency shall proceed to conclude a matter presented to it.” This creates an unambiguous obligation for the FDA to resolve citizen petitions, including by issuing a final decision after a tentative response, without undue delay. Additionally, under 5 U.S.C. § 706(1), courts “shall…compel agency action unlawfully withheld or unreasonably delayed,” providing a judicial lever if the FDA fails to act in a reasonable timeframe.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jan. 1 at 7:12 AM
$BCLI Paragraph 1 The short answer is yes, there is a clear legal obligation, even though no hard deadline exists beyond the initial response window. The FDA’s own regulations under 21 C.F.R. § 10.30 imply that a tentative response is not the end of the process; the regulation explicitly contemplates a future final response and allows the agency to indicate when one may be furnished.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jan. 1 at 7:07 AM
$BCLI Thank you Nick for all the work you and your fellow petitioners did to build this strong legal argument in support of the ALS Community. Most people know my son Matt received 7 doses of NurOwn under the Right-To-Try law between 12/2018 and 6/2020, at the Philadelphia VA, with very positive results. I fully support the Citizens’ Petition and Nick’s recommendation of “next steps”. My key takeaway from Nick’s detailed explanation is that our petition is so strongly crafted in law, and supported by ironclad real-world evidence AND clinical data, that the FDA’s failure to approve the petitioners’ request opens a door for litigation that involves a scorched-earth discovery process. I believe this FDA,upon thorough review of the data, will find they have what they need to “right the wrong” of the prior administration and then further ensure the pathway is clear to move ahead expeditiously. I’m with you Nick -whatever you need, we are here to help.
1 · Reply